Arkema (ENXTPA:AKE), What Is Behind The Latest Attention?

How the Battery Center Expansion Frames Arkema’s Current Profile

Arkema (ENXTPA:AKE) is putting €10 million into expanding its Global Battery Center of Excellence in France, tripling the site’s footprint and upgrading research infrastructure for advanced battery materials.

The move ties directly into Arkema’s wider push on specialty materials and electrification related demand. It also gives its R&D teams tools to test materials under conditions closer to their customers’ cell manufacturing lines.

Recent moves around Arkema, including the €10 million battery center upgrade, the inauguration of a nearly €150 million low carbon acrylic acid unit at Carling, and senior leadership changes in polymers and fluorogases, come against a mixed share performance. The stock has gained 4.01% on a year to date share price basis, but the 5 year total shareholder return is down 40.09%, suggesting current momentum is modest and long term holders have endured a tougher stretch.

Spot under-the-radar electrification plays by comparing Arkema’s battery and low carbon materials push with our curated 43 power grid technology and infrastructure stocks.

Arkema is pouring money and management focus into batteries and low carbon materials while the share price recovery has been limited so far. Is most of the rerating already spent, or is the bigger upside still ahead?

Most Popular Narrative: 14% Undervalued

Arkema’s most followed narrative pegs fair value at €63.63, above the last close at €54.45. This frames the battery and low carbon push as central to the debate over what the shares are worth.

Strong portfolio focus on specialty materials and ongoing cost-optimization initiatives (e.g., structural doubling of annual cost savings to €100 million) improve operational leverage, reduce fixed cost burden, and should ultimately enhance both net margins and cash flow resilience even in cyclically weak environments.

See why 32 investors see Arkema as 14% undervalued.

Result: Fair Value of €63.63 (UNDERVALUED)

Still, the narrative could crack if prolonged weak demand in construction and automotive drags on volumes, or if higher financing costs reduce Arkema’s flexibility.

Find out about the key risks to this Arkema narrative.

Another Take On Arkema’s Valuation

The earlier fair value of €63.63 comes out of a narrative and analyst target framework. A different lens uses Arkema’s P/S of 0.5x, which lines up with its own fair ratio of 0.5x and sits well below the European Chemicals average and peer level of 1x. That gap points to either a valuation cushion or a market that still questions the story. Which side do you think is closer to the truth?

To see how that P/S picture fits with Arkema’s wider fundamentals, take a closer look at our valuation breakdown via See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

There have been mixed messages in the Arkema story so far, or a clear skew in one direction. In either case, it may be useful to move quickly to test the data yourself and weigh both the risks and the potential upside through 2 key rewards and 3 important warning signs.

Looking for more Arkema style investment ideas?

If Arkema’s story has you thinking about what else might be hiding in plain sight, do not stop here. Use the screener to hunt for specific traits and avoid leaving potential opportunities on the table.

• Target resilient upside by focusing on quality businesses that trade below their implied worth through our 179 high quality undervalued stocks.
• Prioritise staying power and financial strength by scanning companies with sturdy balance sheets using the list of solid balance sheet and fundamentals (206 results).
• Hunt for off-the-radar opportunities with strong foundations before the crowd notices through our 620 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com